APA (7th ed.) Citation

JL, B., JE, J., DM, S., ES, J., M, S., JH, S., . . . JC, M. (2014). Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clinical immunology (Orlando, Fla.), 155(2), 176. https://doi.org/10.1016/j.clim.2014.09.012

Chicago Style (17th ed.) Citation

JL, Berkowitz, et al. "Safety, Efficacy, and Pharmacokinetics/pharmacodynamics of Daclizumab (anti-CD25) in Patients with Adult T-cell Leukemia/lymphoma." Clinical Immunology (Orlando, Fla.) 155, no. 2 (2014): 176. https://doi.org/10.1016/j.clim.2014.09.012.

MLA (9th ed.) Citation

JL, Berkowitz, et al. "Safety, Efficacy, and Pharmacokinetics/pharmacodynamics of Daclizumab (anti-CD25) in Patients with Adult T-cell Leukemia/lymphoma." Clinical Immunology (Orlando, Fla.), vol. 155, no. 2, 2014, p. 176, https://doi.org/10.1016/j.clim.2014.09.012.